Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to find out about the safety of sirolimus in individuals with
HIV infection who were also being treated with ART. The investigators wanted to learn whether
sirolimus decreases inflammation and immune activation in the body; whether sirolimus changes
the level of HIV in the participants' blood; and how sirolimus interacts with ART in the
blood. Sirolimus is approved by the Food and Drug Administration (FDA) to prevent organ
rejection in patients aged 13 years and older receiving kidney transplants. Sirolimus had
also been used for the prevention of complications after stem cell transplants and as a
treatment for certain kinds of cancers in HIV-infected patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)